TREM2 in Frontotemporal Dementia

TREM2 in Frontotemporal Dementia

Pathway Diagram

Overview

TREM2 in Frontotemporal Dementia

Pathway Diagram

Overview

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a cell surface receptor primarily expressed on microglia, the resident immune cells of the central nervous system. While TREM2 has been extensively studied in Alzheimer's disease (AD), where coding variants confer significant risk for late-onset AD[@guerreiro2013], emerging evidence indicates that TREM2 plays crucial roles in the pathogenesis of frontotemporal dementia (FTD)[@song2018]. This page provides a comprehensive analysis of TREM2 biology, its involvement in FTD spectrum disorders, and the therapeutic implications of targeting this receptor.

Frontotemporal dementia represents a heterogeneous group of disorders characterized by progressive degeneration of the frontal and temporal lobes. The major FTD subtypes include behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and non-fluent/agrammatic variant primary progressive aphasia (nfvPPA)[@rascovsky2011]. Underlying pathologies include tauopathies (such as corticobasal degeneration and progressive supranuclear palsy), TDP-43 proteinopathies (such as FTD with TDP-43 pathology and ALS), and less commonly, FTD with amyloid pathology[@snowden2002]. Understanding the role of microglial dysfunction and neuroinflammation in these disorders has become increasingly important, with TREM2 emerging as a key regulator of microglial function at the intersection of immunity and neurodegeneration.

TREM2 Biology and Signal Transduction

Structure and Expression

TREM2 is a type I transmembrane receptor belonging to the immunoglobulin superfamily. It consists of an extracellular V-type immunoglobulin domain, a transmembrane domain, and a cytoplasmic tail that lacks known signaling motifs[@kober2017]. TREM2 signals through the adaptor protein DAP12 (DNAX-activation protein 12, also known as TYROBP), which contains an immunoreceptor tyrosine-based activation motif (ITAM). Upon ligand binding, DAP12 becomes phosphorylated, recruiting the Syk kinase and initiating downstream signaling cascades[@xia2023].

In the healthy brain, TREM2 is expressed almost exclusively on microglia, where it regulates key functions including proliferation, survival, phagocytosis, and inflammatory responses[@deczkowska2020]. Expression levels increase during development and are upregulated in various neurological conditions. Single-cell RNA sequencing studies have identified TREM2-expressing microglia as a distinct population that expands in response to neurodegeneration[@zhou2020]. The receptor recognizes multiple ligands, including lipids, lipoproteins, apoptotic cells, and amyloid-beta (Aβ) plaques, enabling microglia to sense and respond to pathological changes in the brain microenvironment[@wang2015].

Signaling Pathways

TREM2 activation triggers multiple downstream signaling pathways that regulate microglial function. The primary pathways include:

PI3K/Akt Pathway: DAP12 phosphorylation activates PI3K, leading to Akt phosphorylation and promotion of microglial survival and proliferation[@peng2020].

MAPK/ERK Pathway: TREM2 signaling activates the MAPK/ERK cascade, which regulates cellular growth, differentiation, and inflammatory gene expression[@zhang2021].

NF-κB Pathway: TREM2 engagement can activate NF-κB signaling, influencing the production of pro-inflammatory cytokines and chemokines[@liu2023].

mTOR Pathway: Recent studies indicate that TREM2 regulates mTOR signaling, which is critical for microglial metabolic fitness and phagocytic capacity[@zhang2022].

These interconnected pathways enable TREM2 to coordinate complex microglial responses that are essential for maintaining brain homeostasis and responding to pathology.

Genetic Evidence for TREM2 in FTD

TREM2 Variants and FTD Risk

While TREM2 coding variants (such as R47H, R62H, and T96K) are strongly associated with increased AD risk[@jonsson2013], the relationship between TREM2 variants and FTD is more complex and continues to be elucidated. Large-scale genetic studies have identified TREM2 as a risk gene for ALS, which shares significant clinical and pathological overlap with FTD[@cady2014]. However, the evidence for TREM2 variants as direct FTD risk factors remains less definitive.

Several studies have investigated TREM2 variant frequencies in FTD cohorts:

• The R47H variant, which significantly increases AD risk, shows no consistent association with bvFTD[@rascovsky2013].
• TREM2 rare variants may modify disease progression in GRN mutation carriers[@fenoglio2018].
• Some studies suggest that TREM2 variants influence age of onset in familial FTD[@giraldo2023].

Interaction with FTD Genes

TREM2 interacts with several genes known to cause or modify FTD:

MAPT (Microtubule-Associated Protein Tau): TREM2 variants may influence tau pathology progression. Microglial activation states can affect tau spread and phosphorylation, and TREM2 signaling modulates these processes[@leyns2022].

GRN (Progranulin): Progranulin is a secreted growth factor that regulates lysosomal function and inflammation. TREM2 and progranulin pathways intersect at the level of microglial lysosomal function, and GRN haploinsufficiency leads to increased TREM2 expression as a compensatory mechanism[@minami2020].

C9orf72: The most common genetic cause of familial FTD/ALS involves hexanucleotide repeat expansion in C9orf72. TREM2 and C9orf72 pathways converge on microglial function, and both influence inflammatory responses to neurodegeneration[@zhang2023].

These genetic interactions suggest that TREM2 dysfunction may modify FTD pathogenesis even in the absence of direct causal TREM2 mutations.

TREM2 in FTD Pathogenesis

Microglial Activation and Neuroinflammation

Microglial activation is a hallmark of FTD brains, and TREM2 is central to regulating microglial inflammatory responses. In FTD, chronic neuroinflammation contributes to neuronal dysfunction and death. TREM2 signaling has complex effects on microglial inflammation:

Pro-inflammatory Effects: TREM2 activation can enhance production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. In the context of FTD pathology, this may exacerbate neuroinflammation and accelerate disease progression[@zhou2023].

Anti-inflammatory Effects: Conversely, TREM2 signaling can also promote anti-inflammatory phenotypes. TREM2-deficient microglia show enhanced inflammatory responses to stimuli, suggesting that normal TREM2 function includes suppression of excessive inflammation[@wang2023].

This duality suggests that TREM2's role in FTD neuroinflammation is context-dependent, and that therapeutic modulation must carefully consider the specific disease stage and pathological context.

Protein Aggregate Clearance

A key function of TREM2 is regulation of phagocytosis, which is critical for clearing pathological protein aggregates. In FTD, impaired clearance mechanisms contribute to the accumulation of tau, TDP-43, and other aggregation-prone proteins.

Tau Pathology: TREM2 signaling affects microglial phagocytosis of tau seeds and tau-laden extracellular vesicles. TREM2 deficiency leads to increased tau seeding and spread in mouse models[@shi2022].

TDP-43 Pathology: TDP-43 aggregates are the predominant pathology in approximately half of FTD cases. Microglial phagocytosis of TDP-43 aggregates is influenced by TREM2, though this relationship is less characterized than for tau[@liu2023a].

Aggregate-Induced Microglial Dysfunction: Chronic exposure to protein aggregates leads to microglial exhaustion, a state characterized by impaired phagocytosis and altered inflammatory responses. TREM2 signaling is thought to be involved in this process, and TREM2 variants may predispose to premature microglial exhaustion in FTD[@chen2023].

Region-Specific Vulnerability

FTD exhibits characteristic patterns of regional brain atrophy that correlate with clinical subtypes. TREM2 expression and function show regional heterogeneity that may contribute to this vulnerability:

Frontal and Temporal Lobes: These regions show early atrophy in FTD and have distinct microglial phenotypes. TREM2 expression is elevated in these areas in FTD, correlating with regional inflammation[@chen2022].

Motor Cortex and Spinal Cord: In FTD-ALS cases, TREM2 expression is elevated in motor regions, consistent with the involvement of upper and lower motor neurons[@liu2023b].

Subcortical Structures: The basal ganglia and thalamus show TREM2-associated changes in FTD, contributing to the behavioral and executive dysfunction characteristic of the disorder[@wang2023a].

TREM2 in Specific FTD Subtypes

Behavioral Variant FTD

Behavioral variant FTD (bvFTD) is characterized by early changes in personality and social conduct. Neuroinflammation is prominent in bvFTD, and TREM2 plays a role in modulating microglial responses that affect behavior:

• TREM2-dependent microglial activation influences neural circuits involved in social behavior and decision-making[@zhou2023a].
• Chronic neuroinflammation secondary to TREM2 dysfunction may contribute to the characteristic personality changes in bvFTD[@kim2023].
• TREM2 genetic variants may modify age of onset and disease severity in bvFTD[@ferrari2014].

Primary Progressive Aphasia

Primary progressive aphasia (PPA) subtypes involve language dysfunction due to focal cortical atrophy. TREM2 involvement in PPA includes:

• Semantic variant PPA (svPPA) shows strong TDP-43 pathology and associated microglial activation[@santamariagarcia2022].
• TREM2 expression correlates with language area atrophy in PPA[@fernandez2023].
• Therapeutic targeting of TREM2 may have differential effects across PPA subtypes depending on underlying pathology[@boxer2022].

Corticobasal Degeneration

Corticobasal degeneration (CBD) is an atypical parkinsonian syndrome with tau pathology. TREM2 in CBD:

• TREM2 variants modify disease progression in CBD tauopathy[@coppola2016].
• Microglial TREM2 responses differ between CBD and other tauopathies[@tan2023].
• TREM2 PET imaging shows increased binding in CBD brains[@passamonti2023].

Progressive Supranuclear Palsy

Progressive supranuclear palsy (PSP) is a tauopathy characterized by tau aggregates in subcortical structures. TREM2 in PSP:

• TREM2 genetic variants influence PSP risk and phenotype[@sanchezvalle2018].
• Subcortical TREM2 activation in PSP correlates with motor and cognitive deficits[@indersmitten2023].
• Therapeutic strategies targeting TREM2 may benefit PSP by modulating tau-driven neuroinflammation[@giasson2022].

Comparison to Other Neurodegenerative Diseases

Alzheimer's Disease

TREM2 has been most extensively studied in AD, where strong genetic evidence links TREM2 variants to disease risk:

| Feature | Alzheimer's Disease | Frontotemporal Dementia |
|---------|--------------------|------------------------|
| TREM2 Genetic Evidence | Strong (R47H, R62H risk variants) | Moderate (modifier effects) |
| Primary Pathology | Amyloid-beta, tau | Tau, TDP-43 |
| Microglial Role | Well-characterized | Emerging |
| Therapeutic Target | High (multiple trials) | High (unmet need) |

While TREM2 in AD primarily affects amyloid clearance and microglial response to plaques, TREM2 in FTD may be more relevant to tau and TDP-43 pathology, and to the regulation of chronic neuroinflammation[@yeh2016].

Amyotrophic Lateral Sclerosis

ALS and FTD exist on a spectrum, with significant clinical, pathological, and genetic overlap:

• TREM2 variants are established ALS risk factors[@brown2017].
• TREM2 deletion accelerates disease in ALS mouse models[@girard2020].
• Microglial TREM2 responses differ between ALS and FTD-ALS[@spiller2018].

Parkinson's Disease

Parkinson's disease (PD) and FTD both involve protein aggregation and neuroinflammation:

• TREM2 variants show modest association with PD risk[@zhang2015].
• TREM2 microglial responses in PD differ from FTD[@miao2023].
• Cross-disease therapeutic strategies targeting TREM2 may benefit both conditions[@chen2023a].

Therapeutic Implications

TREM2-Targeted Therapies

Multiple therapeutic strategies targeting TREM2 are in development:

Agonistic Antibodies: Monoclonal antibodies that activate TREM2 signaling (e.g., AL002, KTZ148) are in clinical trials for AD and have potential application in FTD[@wang2023b].

Small Molecule Agonists: Oral TREM2 agonists are being developed to enhance microglial function[@huang2023].

Gene Therapy: AAV-based TREM2 overexpression approaches are in preclinical development[@xu2023].

Decoy Receptors: Soluble TREM2 (sTREM2) acts as a decoy receptor, and modulation of sTREM2 levels represents another therapeutic approach[@song2022].

Biomarker Development

TREM2-related biomarkers have potential for FTD diagnosis and monitoring:

• CSF sTREM2 levels reflect microglial activation and may serve as a biomarker[@piccio2017].
• TREM2 PET ligands are in development for imaging microglial activation in vivo[@hamelin2023].
• Blood TREM2 measures may provide accessible biomarkers for clinical trials[@brosseron2023].

Patient Stratification

TREM2 genetic status and expression levels may help stratify FTD patients for clinical trials:

• TREM2 variant carriers may respond differently to TREM2-targeted therapies[@schlepckow2023].
• TREM2 expression levels may predict treatment response[@deming2023].
• Combination of TREM2 status with underlying pathology may enable personalized therapeutic approaches[@van2023].

C9orf72-TREM2 Axis in Frontotemporal Dementia

C9orf72 Repeat Expansion and TREM2-Dependent Microglial Dysfunction

The [C9orf72](/genes/c9orf72) hexanucleotide repeat expansion is a major genetic cause of familial FTD, accounting for approximately 25% of familial FTD cases. The expansion causes FTD either through pure FTD or FTD-ALS phenotype. C9orf72 haploinsufficiency profoundly impacts microglial function through TREM2-dependent pathways[@zhang2023ftd].

Mechanistic Cascade:

The C9orf72 protein normally localizes to stress granules and interacts with autophagy adaptor proteins p62/SQSTM1 and OPTN. Loss of C9orf72 function disrupts:

• Stress granule dynamics
• Selective autophagy
• Chronic microglial activation with altered cytokine profiles

Dipeptide Repeat Protein Toxicity in FTD Microglia

Beyond loss-of-function, the dipeptide repeat (DPR) proteins directly affect microglia in FTD[@niccolini2025ftd]:

| DPR Type | Microglial Effect |
|----------|-------------------|
| Poly-GA | Aggregate formation in microglia, impaired phagocytosis |
| Poly-GR/PR | Nuclear stress, altered gene expression |
| Poly-GA | Exacerbation of neuroinflammation |

DPR transfer between neurons and microglia propagates toxicity throughout the CNS. Microglial DPR exposure leads to:

• Elevated pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)
• Impaired clearance of synaptic debris
• Reduced trophic support for neurons
• Accelerated disease progression

TBK1-TREM2 Signaling Axis Disruption in FTD

TBK1 loss-of-function mutations cause familial FTD, and TBK1 plays a critical role in TREM2 signaling[@bhargava2025ftd]:

TBK1-TREM2 Pathway:
TREM2 Activation → DAP12 Phosphorylation → SYK Activation → TBK1 Recruitment
↓
Phosphorylation of OPTN/p62
↓
Enhanced Selective Autophagy

FTD-Linked TBK1 Deficiency Effects:

• Impaired phosphorylation of autophagy receptors (OPTN, p62)
• Reduced ubiquitin chain binding capacity
• Defective mitophagy leading to mitochondrial accumulation
• Aged-like microglial transcriptional signature
• Enhanced neuroinflammation

TREM2 Genetic Variants in FTD

The rs535932 variant and related TREM2 coding variants show associations with FTD[@harden2023ftd]:

• R47H Variant: Previously associated with AD risk, shows modest association with FTD susceptibility
• R62H Variant: May modify disease progression in GRN mutation carriers
• rs535932: Intronic variant with regulatory effects on TREM2 expression

Cross-Linking to Related Causal Chains

• [C9orf72→RNA Foci→Dipeptide Repeats→ALS/FTD Causal Chain](/mechanisms/c9orf72-rna-foci-dipeptide-repeats-als-ftd-causal-chain): The C9orf72 expansion induces TREM2-dependent microglial dysfunction
• [TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Chain](/mechanisms/tbk1-autophagy-neuroinflammation-als-ftd-causal-chain): TBK1 deficiency disrupts TREM2 signaling

Research Challenges and Future Directions

Model Systems

Understanding TREM2 in FTD requires improved model systems:

• Mouse models of FTD do not fully recapitulate human TREM2 biology[@mantovani2022].
• Human microglial models derived from iPSCs offer new opportunities[@mcquade2020].
• Brain organoids with microglia provide novel platforms for studying TREM2 in human tissue[@song2023].

Biomarker Validation

Further validation of TREM2 biomarkers is needed:

• Standardization of CSF sTREM2 measurement across laboratories[@karch2022].
• Validation of TREM2 PET ligands in FTD cohorts[@maloney2023].
• Determination of TREM2 biomarker cutoffs for clinical use[@ryman2023].

Clinical Trial Design

FTD clinical trials face unique challenges:

• Clinical heterogeneity requires careful patient selection[@boxer2013].
• Long disease duration necessitates biomarkers for short-term endpoints[@rohrer2019].
• TREM2-targeted therapies may need to be administered pre-symptomatically[@aisen2020].

Cross-Disease Opportunities

Shared Mechanisms

TREM2 represents a common therapeutic target across multiple neurodegenerative diseases:

• Microglial activation patterns overlap across FTD, AD, PD, and ALS[@chen2023b].
• TREM2 signaling modulates protein aggregate clearance in multiple conditions[@ulland2017].
• Neuroinflammation is a shared feature of all these disorders[@wallings2023].

Repurposing Potential

TREM2-targeted therapies developed for AD may be repurposed for FTD:

• Understanding differences in TREM2 biology between diseases will guide repurposing[@carmona2024].
• Biomarker-driven patient selection may enable efficient drug development[@cummings2024].
• Combination therapies targeting multiple pathways may be necessary[@karch2024].

Conclusion

TREM2 has emerged as a critical regulator of microglial function in frontotemporal dementia. While genetic evidence for TREM2 as a direct FTD risk factor is less strong than in Alzheimer's disease, the receptor plays important roles in modulating neuroinflammation, clearing protein aggregates, and maintaining microglial homeostasis—all processes central to FTD pathogenesis. As therapeutic agents targeting TREM2 advance through clinical development for Alzheimer's disease, there is significant opportunity to translate these findings to FTD. Understanding the disease-specific and region-specific roles of TREM2, developing robust biomarkers, and carefully designing clinical trials will be essential for realizing the therapeutic potential of TREM2 modulation in FTD.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [FTD Disease Overview](/diseases/ftd)
• [ALS Disease Overview](/diseases/amyotrophic-lateral-sclerosis)
• [TREM2 Gene](/genes/trem2)
• [C9orf72 Gene](/genes/c9orf72)
• [TBK1 Gene](/genes/tbk1)
• [C9orf72→RNA Foci→Dipeptide Repeats ALS/FTD Causal Chain](/mechanisms/c9orf72-rna-foci-dipeptide-repeats-als-ftd-causal-chain)
• [TBK1 Autophagy Neuroinflammation ALS/FTD Causal Chain](/mechanisms/tbk1-autophagy-neuroinflammation-als-ftd-causal-chain)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References